ArticleIndian journal of surgical oncology2012
Triple negative breast cancer - our experience and review.
Article in Indian journal of surgical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer.JCO global oncology · 2020Pooled it
- Synthesis, photophysical, computational, and cytotoxicity evaluation of carborane-appended phenylene and triazine trimers: elucidating the role of the central core.RSC advances · 2026Article
- Article
- Article
- Ketone body, as an emerging modulator of metabolic reprogramming and epigenetics in breast cancer.Iranian journal of basic medical sciences · 2025Review
- Article
- Epithelial-to-Mesenchymal Transition and Phenotypic Marker Evaluation in Human, Canine, and Feline Mammary Gland Tumors.Animals : an open access journal from MDPI · 2023Article
- PD-1 and PD-L1 Expression in Indian Women with Breast Cancer.European journal of breast health · 2022Article
- Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2022Article
- The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.Pharmacological reviews · 2022Review
- Article
- Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44Pharmaceuticals (Basel, Switzerland) · 2021Article
- RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2020Article
- Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis.Journal of Cancer · 2020Article
- Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen.International journal of breast cancer · 2020Article
- Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer.Oncology letters · 2018Article
- Epidemiological Study of Triple-Negative Breast Cancer Patients in North Indian Population: a Hospital-Based Study.Indian journal of surgical oncology · 2017Article
- Clinicopathological Study of Triple Negative Breast Cancers.Journal of clinical and diagnostic research : JCDR · 2016Article
- Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Clinical and Cyto-Morphological Characterization of Triple Negative Breast Cancer.Journal of cytologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple negative breast cancer (TNBC) constitutes 10-25% of patients with breast cancer. TNBC is an aggressive phenotype affecting younger age groups and has poor prognosis. We retrospectively analysed 50 triple negative breast cancer patients attending our outpatient department among 270 breast cancer patients. The incidence of TNBC was 18.5%, and most of them were premenopausal 56% (28/50) with mean age was 46.66 ± 13.87 (Range 28-72 years). Most of them had Invasive ductal cancer 94% (47/50) and were high grade (Grade 3-96%)(48/50). Five patients presented with metastatic disease (2 patients only Skeletal, 1 patient with Skeletal and Lung, 1 patient with Lung and 1 patient with Liver) and 7 patients developed recurrence (all 7 had chest wall recurrence, 3 had supraclavicular lymph node recurrence, 2 had skeletal metastases and 1 had developed brain metastases) during follow up. The mean disease free survival was 15 months (Range 3-58 months) and overall survival was 20.14 months (Range 5-70 months). Fifty six percent (28/50) of patients were premenopausal and mean age of presentation was 46.66 ± 13.87 years (Range 28-72 years). Ten percent (5/50) presented with metastatic disease and 15% (7/45) developed metastases during follow up. Five patients (10%) died during follow up. Hence, Triple negative breast cancer is aggressive, with rapid progression leading to mortality in younger patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.